5 Jun 2020 07:00
Concepta PLC
("Concepta" or the "Company")
Notice of Annual General Meeting
Concepta PLC (AIM: CPT), the innovative UK personalised healthcare company and developer of myLotus®, the UK's most accurate home-use fertility tracking and pregnancy self-testing system, announces that the Notice of Annual General Meeting ("AGM") and associated form of proxy will be sent to shareholders today.
The Company's AGM will be held at 52, Ninian Road, Cardiff CF23 5EJ at 11.00am on Thursday 2 July 2020.
In the light of the Government's Stay at Home measures ("Measures") and its advice that non-essential travel and gatherings should be avoided, the Board requests that no shareholders should attend the meeting. Any shareholders (other than the two shareholders referred to below) that do attend will be refused entry. Only two shareholders will attend in person. These shareholders will constitute the minimum quorum for the AGM to take place under the Company's articles of association ("Articles") and company law requirements.
The Company will provide a facility for shareholders to join the AGM online or telephonically. In order to facilitate the process, the Board would request that shareholders register for the meeting before 5.00pm (BST) on Wednesday 1 July 2020. To register for dial-in details please email Walbrook PR at concepta@walbrookpr.com or call +44 (0)20 7933 8787.
Shareholders should note that only the usual and formal business set out in the notice of AGM will be considered at the AGM. The meeting will be conducted swiftly, with a short presentation by the directors but no question and answer session. Accordingly, shareholders wishing to vote on any of the matters of business are urged to do so through completion of a proxy form, which can be submitted to the Company's Registrar. Proxy forms should be completed and returned in accordance with the instructions thereon.
Although the Notes to the Notice of the AGM refer to shareholders being able to appoint a proxy or proxies, the Company would remind shareholders that, in light of the Measures, they will not be allowed entry to the AGM. However, the Company does value shareholder participation and values the votes of shareholders, so it would encourage all shareholders to exercise their voting rights BUT ONLY by appointing the chairman of the AGM to be their proxy. Any proxy received appointing a person other than the chairman of the AGM as the shareholder's proxy will be deemed to have appointed the chairman of the AGM as that shareholder's proxy.
Any shareholder who has a question is invited to contact the Company (by email to the Chairman of the Company, via Walbrook PR at concepta@walbrookpr.com) by 30 June 2020 and the Company will post answers on its website at www.conceptaplc.com after 5.00pm (BST) on Wednesday 1 July 2020.
The Annual Report and Accounts, Notice of AGM and associated form of proxy are available on the Company's website at www.conceptaplc.com.
Concepta plc | www.conceptaplc.com |
Penny McCormick, Chief Executive Officer | via Walbrook PR |
Maddy Kennedy, Chief Financial Officer | |
SPARK Advisory Partners Limited (NOMAD) | Tel: +44 (0)20 3368 3550 |
Neil Baldwin | |
Novum Securities (Broker) | Tel: +44 (0)20 7399 9400 |
Colin Rowbury | |
Walbrook PR Ltd (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or concepta@walbrookpr.com |
Paul McManus | Mob: +44(0)7980 541 893 |
About Concepta PLC (www.conceptaplc.com)
Concepta PLC is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus®, targeted at the personalized mobile health market with a primary focus on hormone testing and increasing a woman's chances of naturally getting pregnant and to provide insight to unexplained infertility.
myLotus® is currently the only consumer product which allows both quantitative and qualitative home (self-test) test measurement of a woman's personal luteinizing hormone (LH) during ovulation and human chorionic gonadotropin (hCG) hormone level during pregnancy, facilitating higher conception rates and early diagnosis of fertility issues. The proposition of myLotus® is to empower women to better understand their hormone levels and menstrual cycle and help women conceive naturally by identifying their window of fertility and optimal time for conception.
The Company has received CE-mark certification for myLotus® and has launched its first product in the UK. The Company is preparing plans to roll-out across the core EU countries in 2020.
myLotus® is expected to be beneficial to users who have been unable to conceive after 6 months of trying. This highly motivated target group of women won't typically be offered medical intervention until after 12 months of unsuccessfully trying to conceive, with IVF not usually offered until after two years of trying to conceive. Research indicates couples start to take positive action ahead of this time typically with little medical support to help them do so.